COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

PrE0905-AML: Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)

Protocol No
PRECOG-PRE0905-AML
Principal Investigator
Sameem Abedin
Phase
II
Summary
The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML
Description
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
Participating Institutions
Froedtert Hospital
Status
IRB INITIAL APPROVAL